Combination therapy of radiofrequency ablation and bevacizumab monitored with power Doppler ultrasound in a murine model of hepatocellular carcinoma

References

• Friedman M, Mikityansky I, Kam A, Libutti SK, Walther MM, Neeman Z, et al. Radiofrequency ablation of cancer. Cardiovasc Intervent Radiol 2004; 27: 427–434
   PubMed Web of Science ®Google Scholar
• Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma: Part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. Am J Roentgenol 2005; 185: 64–71
   PubMed Web of Science ®Google Scholar
• Grenier N, Douws C, Perot V, Ferriere JM, Ravaud A. Combined radiofrequency ablation and antiangiogenic drug for the treatment of recurrent renal tumor. Urology 2009; 73: e11–12
   PubMedGoogle Scholar
• Hines-Peralta A, Goldberg SN. Review of radiofrequency ablation for renal cell carcinoma. Clin Cancer Res 2004; 10: S6328–6334
   PubMedGoogle Scholar
• Wood BJ, Ramkaransingh JR, Fojo T, Walther MM, Libutti SK. Percutaneous tumor ablation with radiofrequency. Cancer 2002; 94: 443–451
   PubMed Web of Science ®Google Scholar
• Mulier S, Ni Y, Jamart J, Michel L, Marchal G, Ruers T. Radiofrequency ablation versus resection for resectable colorectal liver metastases: Time for a randomized trial?. Ann Surg Oncol 2008; 15: 144–157
   PubMed Web of Science ®Google Scholar
• Mulier S, Ni YC, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation – Multivariate meta-analysis and review of contributing factors. Ann Surg 2005; 242: 158–171
   PubMed Web of Science ®Google Scholar
• Lu DS, Raman SS, Vodopich DJ, Wang M, Sayre J, Lassman C. Effect of vessel size on creation of hepatic radiofrequency lesions in pigs: Assessment of the ‘heat sink’ effect. Am J Roentgenol 2002; 178: 47–51
   PubMed Web of Science ®Google Scholar
• Haemmerich D. Effects of micro- and macro-vascular perfusion during radiofrequency tumor ablation. Proc SPIE 2009; 7181: R1–11
   Google Scholar
• Lu DS, Yu NC, Raman SS, Limanond P, Lassman C, Murray K, et al. Radiofrequency ablation of hepatocellular carcinoma: Treatment success as defined by histologic examination of the explanted liver. Radiology 2005; 234: 954–960
   PubMed Web of Science ®Google Scholar
• Schutt DJ, Haemmerich D. Effects of variation in perfusion rates and of perfusion models in computational models of radio frequency tumor ablation. Med Phys 2008; 35: 3462–3470
   PubMed Web of Science ®Google Scholar
• Mertyna P, Hines-Peralta A, Liu ZJ, Halpern E, Goldberg W, Goldberg SN. Radiofrequency ablation: Variability in heat sensitivity in tumors and tissues. J Vasc Interv Radiol 2007; 18: 647–654
   PubMed Web of Science ®Google Scholar
• Mertyna P, Dewhirst MW, Halpern E, Goldberg W, Goldberg SN. Radiofrequency ablation: The effect of distance and baseline temperature on thermal dose required for coagulation. Int J Hyperthermia 2008; 24: 550–559
   PubMed Web of Science ®Google Scholar
• Horkan C, Ahmed M, Liu Z, Gazelle GS, Solazzo SA, Kruskal JB, et al. Radiofrequency ablation: Effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model. J Vasc Interv Radiol 2004; 15: 269–274
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–257
   PubMed Web of Science ®Google Scholar
• Li WW. Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging. Acad Radiol 2000; 7: 800–811
   PubMed Web of Science ®Google Scholar
• Patan S, Munn LL, Jain RK. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: A novel mechanism of tumor angiogenesis. Microvasc Res 1996; 51: 260–272
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039–2049
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004; 100: 2491–2499
   PubMed Web of Science ®Google Scholar
• Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21: 4428–4438
   PubMed Web of Science ®Google Scholar
• Zhao D, Chang CH, Kim JG, Liu H, Mason RP. In vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome. Int J Radiat Oncol Biol Phys 2011; 80: 574–581
   PubMed Web of Science ®Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415–427
   PubMed Web of Science ®Google Scholar
• Jenab-Wolcott J, Giantonio BJ. Bevacizumab: Current indications and future development for management of solid tumors. Expert Opin Biol Ther 2009; 9: 507–517
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–2550
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666–2676
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145–147
   PubMed Web of Science ®Google Scholar
• Huang G, Chen L. Tumor vasculature and microenvironment normalization: A possible mechanism of antiangiogenesis therapy. Cancer Biother Radiopharm 2008; 23: 661–667
   PubMedGoogle Scholar
• Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62
   PubMed Web of Science ®Google Scholar
• Hakime A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, Signoretti S, et al. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: Study in mice. Radiology 2007; 244: 464–470
   PubMed Web of Science ®Google Scholar
• Sabir A, Schor-Bardach R, Wilcox CJ, Rahmanuddin S, Atkins MB, Kruskal JB, et al. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. Am J Roentgenol 2008; 191: 133–139
   PubMedGoogle Scholar
• Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZJ, Goldberg SN. Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology 2006; 240: 82–89
   PubMed Web of Science ®Google Scholar
• Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012; 21: 82–91
   PubMed Web of Science ®Google Scholar
• Drevs J, Schneider V. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis. J Intern Med 2006; 260: 517–529
   PubMed Web of Science ®Google Scholar
• Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: Applications and potential for drug development. J Natl Cancer Inst 2005; 97: 172–187
   PubMed Web of Science ®Google Scholar
• Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol 2003; 76: S60–80
   Google Scholar
• Schor-Bardach R, Alsop DC, Pedrosa I, Solazzo SA, Wang X, Marquis RP, et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?. Radiology 2009; 251: 731–742
   PubMedGoogle Scholar
• Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223–232
   PubMed Web of Science ®Google Scholar
• Forsberg F, Ro RJ, Potoczek M, Liu JB, Merritt CR, James KM, et al. Assessment of angiogenesis: Implications for ultrasound imaging. Ultrasonics 2004; 42: 325–330
   PubMedGoogle Scholar
• Gee MS, Saunders HM, Lee JC, Sanzo JF, Jenkins WT, Evans SM, et al. Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res 2001; 61: 2974–2982
   PubMedGoogle Scholar
• Jugold M, Palmowski M, Huppert J, Woenne EC, Mueller MM, Semmler W, et al. Volumetric high-frequency Doppler ultrasound enables the assessment of early antiangiogenic therapy effects on tumor xenografts in nude mice. Eur Radiol 2008; 18: 753–758
   PubMedGoogle Scholar
• Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS. High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 2002; 62: 6371–6375
   PubMed Web of Science ®Google Scholar
• Lavisse S, Lejeune P, Rouffiac V, Elie N, Bribes E, Demers B, et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 2008; 43: 100–111
   PubMed Web of Science ®Google Scholar
• Hardee ME, Eapen RJ, Rabbani ZN, Dreher MR, Marks J, Blackwell KL, et al. Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+tumors. Cancer Chemother Pharmacol 2009; 63: 219–228
   PubMedGoogle Scholar
• Wang S, Shin IS, Hancock H, Jang BS, Kim HS, Lee SM, et al. Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors. J Control Realease 2012; 162: 218–224
   PubMed Web of Science ®Google Scholar
• Tsushima Y, Funabasama S, Aoki J, Sanada S, Endo K. Quantitative perfusion map of malignant liver tumors, created from dynamic computed tomography data. Acad Radiol 2004; 11: 215–223
   PubMed Web of Science ®Google Scholar
• Van Beers BE, Leconte I, Materne R, Smith AM, Jamart J, Horsmans Y. Hepatic perfusion parameters in chronic liver disease: Dynamic CT measurements correlated with disease severity. Am J Roentgenol 2001; 176: 667–673
   PubMed Web of Science ®Google Scholar
• Breen MS, Breen M, Butts K, Chen L, Saidel GM, Wilson DL. MRI-guided thermal ablation therapy: Model and parameter estimates to predict cell death from MR thermometry images. Ann Biomed Eng 2007; 35: 1391–1403
   PubMed Web of Science ®Google Scholar
• Solazzo S, Mertyna P, Peddi H, Ahmed M, Horkan C, Goldberg SN. RF ablation with adjuvant therapy: Comparison of external beam radiation and liposomal doxorubicin on ablation efficacy in an animal tumor model. Int J Hyperthermia 2008; 24: 560–567
   PubMed Web of Science ®Google Scholar
• Haemmerich D, Chachati L, Wright AS, Mahvi DM, Lee FT, Jr, Webster JG. Hepatic radiofrequency ablation with internally cooled probes: Effect of coolant temperature on lesion size. IEEE Trans Biomed Eng 2003; 50: 493–500
   PubMed Web of Science ®Google Scholar
• Prakash P, Diederich CJ. Considerations for theoretical modelling of thermal ablation with catheter-based ultrasonic sources: Implications for treatment planning, monitoring and control. Int J Hyperthermia 2012; 28: 69–86
   PubMed Web of Science ®Google Scholar
• Osaki T, Takagi S, Hoshino Y, Okumura M, Fujinaga T. Antitumor effects and blood flow dynamics after photodynamic therapy using benzoporphyrin derivative monoacid ring A in KLN205 and LM8 mouse tumor models. Cancer Lett 2007; 248: 47–57
   PubMedGoogle Scholar
• Le Serve AW, Hellmann K. Metastases and the normalization of tumour blood vessels by ICRF 159: A new type of drug action. Br Med J 1972; 1: 597–601
   PubMed Web of Science ®Google Scholar
• Ansiaux R, Baudelet C, Jordan BF, Crokart N, Martinive P, DeWever J, et al. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy. Cancer Res 2006; 66: 9698–9704
   PubMedGoogle Scholar
• Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13: 3942–3950
   PubMed Web of Science ®Google Scholar
• Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 3731–3736
   PubMed Web of Science ®Google Scholar
• Vlahovic G, Rabbani ZN, Herndon JE, 2nd, Dewhirst MW, Vujaskovic Z. Treatment with imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer 2006; 95: 1013–1019
   PubMed Web of Science ®Google Scholar
• Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6: 553–563
   PubMed Web of Science ®Google Scholar
• Roca C, Primo L, Valdembri D, Cividalli A, Declerck P, Carmeliet P, et al. Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res 2003; 63: 1500–1507
   PubMed Web of Science ®Google Scholar
• Goldberg SN, Kamel IR, Kruskal JB, Reynolds K, Monsky WL, Stuart KE, et al. Radiofrequency ablation of hepatic tumors: Increased tumor destruction with adjuvant liposomal doxorubicin therapy. Am J Roentgenol 2002; 179: 93–101
   PubMed Web of Science ®Google Scholar
• Ahmed M, Liu Z, Lukyanov AN, Signoretti S, Horkan C, Monsky WL, et al. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: Effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology 2005; 235: 469–477
   PubMed Web of Science ®Google Scholar
• Ahmed M, Monsky WE, Girnun G, Lukyanov A, D’Ippolito G, Kruskal JB, et al. Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res 2003; 63: 6327–6333
   PubMed Web of Science ®Google Scholar
• Monsky WL, Kruskal JB, Lukyanov AN, Girnun GD, Ahmed M, Gazelle GS, et al. Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. Radiology 2002; 224: 823–829
   PubMed Web of Science ®Google Scholar
• Solazzo SA, Ahmed M, Schor-Bardach R, Yang W, Girnun GD, Rahmanuddin S, et al. Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology 2010; 255: 62–74
   PubMed Web of Science ®Google Scholar
• Wood BJ, Poon RT, Locklin JK, Dreher MR, Ng KK, Eugeni M, et al. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J Vasc Interv Radiol 2012; 23: 248–255
   PubMed Web of Science ®Google Scholar